Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours

Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing a combination of epacadostat plus pembrolizumab in 62 patients with advanced solid tumours shows objective responses in 12 of 22 patients (55%) with melanoma and in patients with other solid tumours, such as renal cell carcinoma (RCC). Severe and life-threatening side effects were reported by […]

read more

Advanced Kidney Cancer Centre of Excellence

The Advanced Kidney Cancer Center of Excellence from UroToday and GU OncToday delivers disease, treatment and guidelines information in this rapidly changing area. This series of articles explores ongoing clinical trials, including trials looking at biomarkers and genomic data, in addition to live conference coverage that will provide real-time perspectives from Dr Sumanta Kumar Pal and […]

read more

Rethinking the communication of clinical trial results

The following article discusses the means by which clinical trial results are communicated to clinicians and patients. The article suggests that if clinical trial results were more quickly and openly accessible, medical improvements would be implemented more swiftly too, and asks what can be done to ease this process? What isn’t working and how can […]

read more
Showing all 4 results